<DOC>
	<DOC>NCT01494727</DOC>
	<brief_summary>The objectives of this study are: - To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers - To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers</brief_summary>
	<brief_title>Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Male volunteers in the age between 20 and 45 years old Body Mass Index (BMI) in the range of 19 to 27 kg/m2 History of allergy or sensitivity to any drug, including amlodipine or valsartan History of clinically significant hepatic, renal, gastrointestinal, neurology, pulmonary, endocrine, musculoskeletal, hematologic, oncologic, psychiatric, especially cardiovascular disease History of surgery except or gastrointestinal diseases which might significantly change absorption of medicines Hypotension (Systolic Blood Pressure(SBP) ≤ 100 mmHg or Diastolic Blood Pressure(DBP) ≤ 65 mmHg) Hypertension (SBP ≥ 150 mmHg or DBP ≥ 95 mmHg) Clinical laboratory test values are outside the accepted normal range Aspartate Transaminase(AST) or Alanine Transaminase(ALT) &gt; 1.25 times to normal range Total bilirubin &gt; 1.25 times to normal range Positive for Hepatitis B Virus surface Antigen(HBsAg), Hepatitis C Virus Antibody(HCVAb) or Human Immunodeficiency Virus Antibody(HIVAb)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>